Beta Bionics (NASDAQ: BBNX) director sells 2,811 shares in planned trade

Rhea-AI Filing Summary

Beta Bionics, Inc. director Christy Jones reported an open-market sale of 2,811 shares of Common Stock at $14.00 per share. The transaction was executed on June 4, 2026 pursuant to a pre-arranged Rule 10b5-1 Plan adopted on February 19, 2026. After this sale, Jones directly holds 27,400 shares, indicating she retains a substantial ongoing equity position in the company.

Insights

Equity compensation and insider-trading analyst

Routine planned sale by director under 10b5-1 plan with sizable holdings remaining.

Director Christy Jones conducted an open-market sale of 2,811 shares of Beta Bionics, Inc. Common Stock at $14.00 per share. The transaction is classified as a sale and leaves her with 27,400 directly held shares, which still represents a meaningful personal stake.

The footnote states the sale was made under a pre-established Rule 10b5-1 Plan adopted on February 19, 2026. Such plans are designed to schedule trades in advance, reducing the significance of trade timing as a signal of insider sentiment.

There are no derivative positions reported in this filing, and no indication of exercises or tax-related dispositions. Overall, this appears to be a routine liquidity event by a director who continues to maintain a notable equity position in the company.

Insider Trade Summary 10b5-1

Net Seller: 2,811 shares ($39,354)

Net Sell 1 txn

Insider Jones Christy

Role null

Sold 2,811 shs ($39K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,811	$14.00	$39K

Holdings After Transaction: Common Stock — 27,400 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 2,811 shares Sale price: $14.00 per share Shares held after sale: 27,400 shares +2 more

5 metrics

Shares sold 2,811 shares Open-market sale on June 4, 2026

Sale price $14.00 per share Price for Common Stock sold

Shares held after sale 27,400 shares Direct ownership following transaction

Transaction code S Sale in open market or private transaction

Plan type Rule 10b5-1 Plan Plan adopted February 19, 2026

Key Terms

Rule 10b5-1 Plan, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 Plan regulatory

"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on February 19, 2026."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jones Christy

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		S(1)		2,811	D	$14	27,400	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on February 19, 2026.

	/s/ Stephen Feider, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Beta Bionics (BBNX) director Christy Jones do in this Form 4?

Director Christy Jones sold 2,811 shares of Beta Bionics Common Stock at $14.00 per share in an open-market transaction. Following the sale, she continues to hold 27,400 shares directly, maintaining a meaningful ownership stake in the company.

At what price were the Beta Bionics (BBNX) shares sold by Christy Jones?

Christy Jones sold 2,811 shares of Beta Bionics Common Stock at a price of $14.00 per share. This price reflects the execution level for the open-market sale reported, not a broader valuation measure for all company shares.

How many Beta Bionics (BBNX) shares does Christy Jones own after the reported sale?

After the transaction, Christy Jones directly holds 27,400 shares of Beta Bionics Common Stock. This post-transaction balance shows she retained a substantial equity position even after selling 2,811 shares in the open market.

Was the Beta Bionics (BBNX) insider sale made under a Rule 10b5-1 plan?

Yes. The reported sale was executed under a Rule 10b5-1 Plan adopted on February 19, 2026. Such plans pre-schedule trades, so the timing of this 2,811-share sale is less indicative of short-term views on the stock.

Does this Beta Bionics (BBNX) Form 4 include any option exercises or derivatives?

No. The Form 4 only shows an open-market sale of 2,811 shares of Common Stock. The derivative section is empty, indicating there were no reported option exercises, conversions, or other derivative security transactions in this particular filing.